Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris

Hui, Hai-Zhen; Wang, Yingjun; Cheng, Jia-Rong; Mao, Han; Guo, Hongqian; Quan-ping, Diao; Shi, Bing-Jun

doi:10.1097/mjt.0000000000001620

American Journal of Therapeutics

2023

DOI: 10.1097/mjt.0000000000001620

|View full text |Cite

Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris

Hai-Zhen Hui

Yingjun Wang

Jia-Rong Cheng

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But before this, there has been report of camrelizumab associated with psoriasis, which was another PD-1 inhibitor. 4 Some researchers suggest that Th17 cells play an essential role in the pathogenesis of psoriasis, and the PD-1 pathway downregulates the expression of Th17 cells. Through inhibiting PD-1, sintilimab may increase Th17 cells activation that induces psoriatic lesions.…”

mentioning

confidence: 99%

Sintilimab-Associated Psoriasis

Wei,

Lin,

Jia

et al. 2024

American Journal of Therapeutics

View full text Add to dashboard Cite

mentioning

confidence: 99%

Sintilimab-Associated Psoriasis

Wei,

Lin,

Jia

et al. 2024

American Journal of Therapeutics

View full text Add to dashboard Cite

SARS-COV-2-vaccine-inactivated-Sinovac-Biotech

2024

Reactions Weekly

View full text Add to dashboard Cite

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Wu,

Huang,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background: Cases of autoimmune bullous dermatosis (AIBD) have been reported following COVID-19 vaccination. Objective: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination. Methods: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting ≥ 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine. Results: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation. Conclusions: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris

Cited by 3 publications

References 10 publications

Sintilimab-Associated Psoriasis

Sintilimab-Associated Psoriasis

SARS-COV-2-vaccine-inactivated-Sinovac-Biotech

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Contact Info

Product

Resources

About